Nicotine gum 4 mg access in India: experts urge OTC availability for smoking cessation
Public health experts and clinicians are urging policymakers in India to remove prescription requirements for nicotine gum up to 4 mg, citing long-standing global use and WHO endorsement. They say nicotine gums are regulated therapeutic products under the Drugs and Cosmetics Act, 1940, and can help dependent smokers quit combustible tobacco when made more accessible.
Business
Public health experts and clinicians have asked policymakers to remove prescription limits on nicotine gums up to 4 mg. The group said easier access could help smokers quit. The request came amid wider public debate around nicotine products. Experts said nicotine gum should be treated differently from newer nicotine formats.
Nicotine gum comes in 2 mg and 4 mg strengths and has been used for over 30 years. The World Health Organization has backed it as a quit aid. Nicotine gum also appears on the WHO Essential Medicines List. Experts said these products are designed to support smokers trying to stop combustible tobacco use.
Nicotine gum 4 mg rules in India under Drugs and Cosmetics Act
In India, nicotine gums are medicinal products under the Drugs and Cosmetics Act, 1940. Experts said this separates gums from nicotine pouches and other newer delivery formats. Nicotine gums sit under Schedule K exemptions in the Drugs and Cosmetics Rules. The exemptions aim to improve access to essential public health interventions.
Till one and a half years back, nicotine gums up to 4 mg was sold over the counter under Schedule K drugs in India. Experts now want a return to wider access for both strengths. They argued that prescription-only limits can slow quitting attempts. They also said such limits create barriers for people who need help quickly.
Nicotine gum 4 mg evidence from WHO and Cochrane Reviews
Dr Meenakshi N, Family Physician, Public Health Specialist & Clinical Researcher, Apollo Hospital in Noida, UP, said, “It is critical to separate fear from facts. Nicotine gums are not initiation products; they are therapeutic tools. Extensive global evidence shows that regulated NRT delivers controlled nicotine without exposure to tar, carbon monoxide or the 7,000 toxic chemicals present in cigarettes.\”
Experts cited Cochrane Reviews 2021, which found nicotine replacement therapy improves long-term quit rates. The review reported a 50-70 per cent rise versus unaided attempts. They also pointed to WHO’s 2024 Tobacco Cessation Guidelines. The guidelines list 2mg and 4mg gums as first-line treatments.
The WHO guidance also said the 4mg dose suits smokers with higher nicotine dependence. Experts also referred to global safety findings on therapeutic NRT use. They said data show no meaningful rise in cardiovascular events. This included patients with heart disease, when used as directed by the US FDA.
Nicotine gum 4 mg safety and DTAB position in India
The Drugs Technical Advisory Board DTAB has discussed oral NRTs and their misuse risk. Experts said DTAB has repeatedly noted a low abuse potential for such products. DTAB retained 2mg gum as an OTC option. DTAB also noted no conclusive evidence of widespread misuse of higher-dose gums when used therapeutically.
Dr Rajesh Madan, Senior Consultant Cardiologist, Max Hospital, Dwarka, noted, \”Nicotine itself is not risk-free, but the harm profile of medicinal nicotine is dramatically lower than smoking. The real danger lies in denying dependent smokers access to effective cessation tools, especially in low-resource settings.\”
Nicotine gum 4 mg access, quit attempts, and equity concerns
India has over 100 million smokers, as per GATS-2, Ministry of Health, 2022. Experts said nearly 98 per cent of quit attempts fail without pharmacological support. They said prescription hurdles hit rural and low-income groups harder. A section of experts linked this to the National Tobacco Control Programme NTCP and Article 21.
Nicotine gum 4 mg OTC use in other countries
More than 100 countries allow both 2mg and 4mg nicotine gums as OTC products. The list includes the United States, the United Kingdom, Canada, Australia and most of the European Union. Experts said none reported higher youth initiation due to medicinal gum access. They said the experience supports wider availability under regulation.
R Benjamin, Behaviour Therapist, Psychologist at Shambhave Wellness, Gurgaon, Haryana, added, \”The global lesson is clear: easier access to regulated NRT reduces smoking prevalence. Restricting therapeutic doses does not protect youth; it only prolongs tobacco addiction among adults.\”
Public health experts said policy should weigh comparative risk rather than fear. They noted cigarettes kill 1.35 million Indians every year. They also said NRT is among the safest pharmacological interventions in modern medicine. Experts said progress on SDG 3.4 needs evidence-based quitting support and stricter action on non-therapeutic nicotine products.
With inputs from PTI